NLRP3 and arrhythmogenic right ventricular cardiomyopathy: Inhibition of NLRP3 with MCC950 in Dsg2mut/mut ARVC mice significantly reduced right ventricular dilation, dysfunction and malignant arrhythmias, highlighting NLRP3 as a potential therapeutic target for mitigating cardiac inflammation and remodelling in ARVC (Figure 3C) [63].